We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Glaxo Loses Patent For Seretide/Advair In U.K.

Law360 (March 19, 2004, 12:00 AM EST) -- GlaxoSmithKline has lost a U.K. patent challenge from generic drug makers Cipla and Ivax on its top-selling athma drug Seretide (Advair).

Justice Pumfrey with the High Court ruled Friday that the patent for Seretide was “entirely obvious” and invalidated it.

Glaxo said it was considering whether to appeal the decision.

The case rested on whether Glaxo’s scientists took a truly inventive step in combining two older drugs, Flovent and Serevent, to make Seretide.

Cipla and Ivax had argued that the patent for the inhaled asthma treatment,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.